• AFYREN

  Led · Grant · May 2026

  AFYREN develops bio-based, low-carbon ingredients through innovative fermentation technology for use in sustainable industrial applications. The company is investing in its flagship AFYREN NEOXY biorefinery, which it now fully owns and is upgrading through an ongoing investment program. AFYREN has secured public support for these investments, including a €3 million grant from the Grand Est Region supported by the European Just Transition Fund and prior installments under Bpifrance’s France Relance initiative. Management says the investments aim to reinforce industrial assets, create jobs, and build sustainable skills in the region. The company announced it met the milestones required to obtain the final grant installment, and previously received a €2.2 million final installment in March 2026 under the same program.

• ADEMUS

  Participated · Equity · May 2024

  Ademus designs and manufactures electric motorcycles in its Toul (Meurthe‑et‑Moselle) workshops under the Medusa brand. Founded in 2020 by Arts et Métiers engineer Thomas Salquebre, the company emphasizes sensory riding experiences and has developed a controllable, disconnectable mechanical‑style sound for its bikes. It completed initial prototyping to demonstrate disruptive technical systems that differentiate its motorcycle from competitors. Ademus plans to accelerate prototype road testing, offer its technologies to actors in the automotive value chain, and expand its team. The company recently closed a €600,000 fundraising and is supported by Yeast, Groupe ILP, Bpifrance, Région Grand Est, Caisse d’Epargne and local business angels. Management says the next fundraising will target homologation and industrialization of the motorcycle and its technologies.

• BiPER Therapeutics

  Participated · Grant · Feb 2023

  Founded in 2021, BiPER Therapeutics engineers innovative small molecules that induce lethal cellular stress to destroy tumors. Its lead candidate, BPR001-615, has already demonstrated in-vitro and in-vivo efficacy both as a monotherapy and in combination with standard chemo- and immunotherapies for gastrointestinal cancers. The company plans to file clinical trial applications in Europe and the United States in Q1 2026. Fresh capital will also finance the opening of a second, AI-driven R&D center in Tunis to expand the company’s pipeline into additional oncology and non-oncology indications. BiPER currently employs 11 people and has secured just over €3 million to date, including the recent i-Lab 2022 innovation prize. Management ultimately aims to raise a €30 million Series A round to take BPR001-615 to clinical proof of efficacy.

• RDS

  Participated · Grant · Feb 2021

  RDS is a medtech company focused on remote patient monitoring. Its flagship product, MultiSense, is a patented telemonitoring system that the company develops, manufactures and markets. The company collaborates with international research initiatives such as DARE and 5G-OR and has been incubated at SEMIA/Quest for Health while being accelerated by PariSanté Campus. Emphasizing an eco-conscious approach, RDS aims to set new standards for telemonitoring across Europe. With its latest funding, the firm plans to expand commercialization in France, Germany and the broader European market and to conduct additional clinical trials to support reimbursement applications. The team is simultaneously preparing for FDA registration with the goal of entering the U.S. market in 2028. Elie Lobel leads the company as CEO, and no revenue or user metrics have been disclosed.

• Dianosic

  Participated · Equity · Apr 2020

  Dianosic is a biotechnology company specializing in nasal drug-delivery solutions, notably a biorésorbable nasal implant. The implant is designed to treat chronic allergic rhinitis and rhinosinusitis. The company is also developing nose-to-brain delivery approaches aimed at neurological diseases such as Parkinson's and Alzheimer's. Dianosic announced a €7 million fundraising to accelerate its clinical and industrial development. The round is led by Aptar (Illinois), a global leader in drug-delivery systems, with participation from Noshaq (Liège), Capital Grand Est (Strasbourg) and Finovam Gestion (Lille). Co-founder and president Philippe Bastide said the financing validates the technology and will speed the company’s clinical and industrial progress. Dianosic develops therapeutic solutions for debilitating ENT conditions, including the ARIS family of treatments and the commercial CAVI-T device. The company intends to use new funding to finance a preclinical in vivo study and to launch a phase I clinical trial of its ARIS-R solution for chronic allergic rhinitis. In parallel it will continue developing ARIS-S for chronic sinusitis and explore other ENT applications. Dianosic also plans to use the funds to enhance the technical capability of its team. The company co-founded by Marc Augustin and CEO Philippe Bastide counts Prof. Christian Debry as scientific advisor. Its CAVI-T asymmetrical intranasal balloon is CE-marked, FDA-registered, and has been commercially available in Europe and the Middle East since 2021. Dianosic develops innovative medical devices for the management of ENT conditions. Its core product is CAVI-T, an asymmetrical intranasal balloon for hemostasis that stops spontaneous or postoperative nasal bleeding with low-pressure compression; CAVI-T was CE-marked in February 2020 and is patent-protected in France with planned coverage in Europe, the US, Japan and China. The company is also developing the Active Resorbable Intranasal Scaffold (ARIS) to deliver steroids for long-term (12-month) management of chronic sinusitis without requiring prior surgery. Dianosic intends to use its new funding to support the European launch of CAVI-T and to pursue ARIS development. The company was founded in July 2017 by Marc Augustin, Philippe Bastide and Pr Christian Debry and is incubated by SEMIA with support from the Grand Est regional ecosystem. Financially, Dianosic closed a first funding round of more than €1.5M in a mix of capital and non-dilutive funding.

No current team members are available.